The 19th Annual EU Pharmaceutical Law Forum
Leading legal opinion on the years most high profile cases and regulatory reforms
The must attend meeting for General Counsel in pharmaceutical companies and lawyers in private practice advising the pharmaceutical sector. Don’t miss this opportunity to get a complete round-up of the past 12 months most important legal decisions and get business critical information on key areas for 2010.
Feedback from and access to officials from European Medicines Agency and EU Commission
- Nathalie Rampal Olmedo, Legal Adviser, Legal Service, European Medicines Agency
- Blaz Visnar, European Commission
- Olivér Várhelyi, Head of Unit, Internal Market and Services DG, Industrial Property Unit (D2), European Commission
Highlights of EU Pharmaceutical Law Forum 2010
Reviewing the past 12 months and looking to the future
- Trade and regulatory reviews: New legislation and case law read more
- Application of competition law to the pharma sector read more
- Understand what has been learnt as a result of the sector inquiry and possible implications. read more
- Legal perspectives on current regulatory developmen read more
- Bringing together top level legal know-how read more
- Creating a forum which encourages discussion and the exchange of knowledge read more
No speakers found for this page.
Dates and Venues
No dates were found
Those who attend include senior legal professionals from in-house counsel and private practice
- Advocaat
- Associate
- Attorney
- Chief Legal Officer
- Corporate Counsel
- Corporate Regulatory Affairs Manager
- Director Legal Affairs
- Head Legal Affairs
- Managing Partner
Attendees to date
Kroman Reumert-Attorney
Houthoff Buruma-Attorney at Law
Pavia e Ansaldo-Partner
Genzyme Europe BV-Senior Director Legal Europe
Kancelaria Radcy Prawnego-Partner
Gorrissen Federspiel Kierkegaard-Partner Attorney at Law
Vejmelka & Wuensch VOS-Partner
Amgen Europe GmbH-VP Legal Affairs
Amgen Europe GmbH-Senior Counsel
Amgen Europe GmbH-Associate Counsel
Amgen Europe GmbH-Senior Counsel
Amgen Europe GmbH-Associate General Counsel
Allergan Ltd-VP & General Counsel
KNMP-Lawyer
Johnson & Johnson-Assistant General Counsel
Baker & Mckenzie-Partner
Wolf Theiss-Partner
Wolf Theiss-Attorney
Arthur Cox-Solicitor
Arthur Cox-Partner
Arthur Cox-Partner
Advokatfirman Delphi-Senior Associate
Advokatfirman Delphi-Part
AstraZeneca-Senior Counsel
Sanofi Aventis Groupe-Associate Vice President
Elan Pharma International Ltd-Vice President Legal & Counsel
Johnson & Johnson-Senior Legal Counsel
Almati International Trust
European Medicines Agency-Legal Adviser
Mehmet Gun & Partners-Partner
Mehmet Gun & Partners-Advocate
Mehmet Gun & Partners-Advocate
Shire Pharmaceuticals Group-Senior Vice President
Shire Pharmaceuticals Group-Vice President
Shire Pharmaceuticals Group-Legal Counsel
Oppenlander Rechtsanwalte-Partner
GlaxoSmithKline Biologicals SA-Director Senior Counsel
GlaxoSmithKline Biologicals SA-Director
Napp Pharmaceauticals-Senior legal advisor
Amgen-Associate General Counsel
Sanofi Aventis SpA-Legal Manager
Studio Legale Bird & Bird-Lawyer
Kroman Reumert-Partner
Bird & Bird-Senior Associate
Biogen Idec International GmbH-International Counsel
Biogen Idec International GmbH-Vice President
Biogen Idec International GmbH-International Counsel
5 May 2010: New 1/2 day workshop
How to Manage an Outsourcing Transaction to Ensure Regulatory Compliance and Get Best Value
3 Key Sessions
- Outsourcing – A risk analysis
- Strategies to mitigate regulatory risks in outsourcing deals
- Strategies to minimise commercial risks and drive best value from an outsourcing transaction
Led by: Toby Crick, hazel Grant & Georgia Gavriilidou, Bristows
Media Partners
Poll
What area of the EU’s current regulatory framework on biosimilars is most in need of reform?
Reviews
"An invaluable review of recent developments in EU pharma law and a unique insight into what is coming Partner"
"Very informative with good presentations with very good knowledge"
